Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib

Publisher： Karger

E-ISSN： 1423-0143|35|6|468-476

ISSN： 1420-4096

Source： Kidney and Blood Pressure Research, Vol.35, Iss.6, 2012-06, pp. : 468-476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines

By  

Kidney and Blood Pressure Research, Vol. 35, Iss. 1, 2011-08 ,pp. : 18-25

Karger

Access to resources Recommend Favorite

Circulating Endothelial Progenitor Cell Levels Predict Cardiovascular Events in End-Stage Renal Disease Patients on Maintenance Hemodialysis

By  

Nephron, Vol. 130, Iss. 3, 2015-06 ,pp. : 151-158

Karger

Access to resources Recommend Favorite

Serum Vascular Endothelial Growth Factor Is a Candidate Biomarker of Renal Cell Carcinoma in Hemodialysis Patients

By  

Nephron, Vol. 84, Iss. 1, 2000-01 ,pp. : 83-84

Karger

Access to resources Recommend Favorite

Novel Approach to Cardiovascular Outcome Prediction in Haemodialysis Patients

By  

American Journal of Nephrology, Vol. 43, Iss. 3, 2016-04 ,pp. : 143-152

Karger

Access to resources Recommend Favorite

Renal Cell Carcinoma in the Allograft: What Is the Role of Polyomavirus

By  

Case Reports in Nephrology and Dialysis, Vol. 2, Iss. 2, 2012-09 ,pp. : 125-134

Karger

Access to resources Recommend Favorite